Form 4: Atea Pharmaceuticals Director Franklin M. Berger Increases Stake with Recent Share Purchases

Director Franklin M. Berger of Atea Pharmaceuticals, Inc. has acquired 25,000 shares of common stock in multiple transactions over two days.

Summary

• Franklin M. Berger, a director at Atea Pharmaceuticals, Inc., has reported purchasing 15,000 shares of common stock on January 15, 2025, at a weighted average price of $3.1923 per share.
• The shares were bought in multiple transactions with prices ranging from $3.165 to $3.21.
• On January 16, 2025, Mr. Berger purchased an additional 10,000 shares at a weighted average price of $3.3614 per share.
• These shares were also purchased in multiple transactions with prices ranging from $3.32 to $3.405.
• Following these transactions, Mr. Berger's total direct holdings in Atea Pharmaceuticals increased to 476,897 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the director's purchase of shares suggests confidence in the company, but it's a routine transaction and not a major event.

Positives

• The director's purchase of shares indicates confidence in the company's future prospects.
• The increased stake by a director can be seen as a positive signal to the market.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in the pharmaceutical industry. It provides transparency into the actions of company directors and their confidence in the company's stock.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies, particularly in the pharmaceutical sector where directors and officers often have significant holdings.
• The reported transactions are within the normal range of insider trading activity and do not indicate any unusual or concerning behavior.
• Similar filings are regularly made by directors and officers of comparable companies such as Gilead Sciences (GILD) and Moderna (MRNA), reflecting their personal investment decisions.

Stakeholder Impact

• The share purchases may positively influence investor sentiment.
• The increased stake by a director could be seen as a positive signal to the market.

Key Dates

Keywords

Atea Pharmaceuticals, AVIR, Franklin M. Berger, insider trading, share purchase, director, common stock, SEC Form 4